SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma informs about updates

13 Apr 2026 Evaluate
With reference to it letter dated 11th December, 2025 regarding US FDA Inspection at company’s manufacturing facility located at Lexington, (Kentucky, USA). Piramal Pharma has informed that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection. The intimation is being submitted today being the first working day after receipt of the said EIR.

The above information is a part of company’s filings submitted to BSE.  

Piramal Pharma Share Price

146.50 0.40 (0.27%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×